Table 3 General information of sMPLCs before and after matching

Age, years ± SD

62.0 ± 7.4

57.0 ± 10.7

3.25

0.001

61.6 ± 7.6

59.3 ± 10.6

1.18

0.243

Sex, n (%)

3.06

0.080

0.40

0.527

 Male

28 (43.1%)

22 (28.9%)

19 (38.8%)

16 (32.7%)

 Female

37 (56.9%)

54 (71.1%)

30 (61.2%)

33 (67.3%)

Largest tumor size (mm)

22.0 ± 12.5

12.1 ± 7.6

17.7

0.000

17.1 ± 7.4

13.57 ± 8.9

2.14

0.035

 < 20 mm

29 (44.6%)

70 (92.1%)

38.8

0.000

29 (59.2%)

43 (87.8%)

10.26

0.001

 ≥ 20 mm

36 (55.4%)

6 (7.9%)

20 (40.8%)

6 (12.2%)

Secondary lesion size (mm)

11.7 ± 6.4

7.7 ± 3.3

4.77

0.000

10.0 ± 5.6

8.3 ± 3.5

1.83

0.071

 < 10 mm

26 (40.0%)

54 (71.1%)

15.2

0.000

25 (32.1%)

33 (66.7%)

2.12

0.146

 ≥ 10 mm

39 (60.0%)

22 (28.9%)

23 (59.2%)

16 (33.3%)

Tumor number

0.99

0.608

1.26

0.532

 2

54 (83.1%)

64 (84.2%)

40 (81.6%)

41 (83.7%)

 3

11 (16.9%)

11 (14.5%)

9 (18.4%)

7 (14.3%)

 ≥ 4

0 (0%)

1 (1.3%)

0 (0%)

1 (2.0%)

Main lesion staging

9.79

0.044

1.76

0.622

 IA

51 (78.5%)

72 (94.8%)

43 (87.8%)

46 (93.9%)

 IB

3 (4.6%)

0 (0%)

0 (0%)

0 (0%)

 IIA

3 (4.6%)

1 (1.3%)

1 (2.0%)

0 (0%)

 IIB

2 (3.1%)

0 (0%)

1 (2.0%)

1 (2.0%)

 IIIA

6 (9.2%)

3 (3.9%)

4 (8.2%)

2 (4.1%)

Smoking

1.2

0.273

0.08

0.779

 Yes

13 (20.0%)

10 (13.2%)

7 (14.3%)

8 (16.3%)

 No

52 (80.0%)

66 (76.8%)

42 (87.5%)

41 (84.7%)

Family history of lung cancer

0.01

0.918

0.71

0.399

 Yes

4 (6.1%)

5 (6.6%)

2 (4.1%)

4 (8.2%)

 No

61 (93.9%)

71 (93.4%)

47 (95.9%)

45 (91.8%)

Histologic type

6.43

0.169

7.12

0.870

 Double adenocarcinoma

54 (83.1%)

71 (93.5%)

43 (87.8%)

45 (91.9%)

 Double squamous

8 (12.3%)

2 (2.6%)

4 (8.2%)

2 (4.1%)

 Adenocarcinoma-squamous

1 (1.5%)

1 (1.3%)

1 (2.0%)

1 (2.0%)

 Squamous-adenocarcinoma

1 (1.5%)

0 (0%)

0 (0%)

0 (0%)

 Other

1 (1.5%)

2 (2.6%)

1 (2.0%)

1 (2.0%)

Differentiation

21.7

0.000

4.98

0.083

 High

25 (38.5%)

57 (75.0%)

25 (51.0%)

34 (69.4%)

 Moderate

18 (27.7%)

13 (17.1%)

11 (22.4%)

10 (20.4%)

 Poorly

22 (33.8%)

6 (7.9%)

13 (26.6%)

5 (10.2%)

Complications

3.69

0.297

7.49

0.112

 0

35 (53.8%)

31 (40.8%)

25 (51.0%)

16 (32.7%)

 1

17 (26.2%)

31 (40.8%)

12 (24.5%)

23 (46.9%)

 2

11 (16.9%)

11 (14.5%)

9 (18.4%)

8 (16.3%)

 ≥ 3

2 (3.1%)

3 (3.9%)

3 (6.1%)

2 (4.1%)

Simultaneous surgery

5.25

0.022

7.51

 Yes

51 (78.5%)

46 (60.5%)

38 (77.6%)

25 (51.0%)

0.006

 No

14 (21.5%)

30 (39.5%)

11 (22.4%)

24 (49.0%)

Second tumor surgery method

37.7

0.000

15.68

 Lobectomy

36 (55.4%)

6 (7.9%)

24 (49.0%)

6 (12.2%)

 Segmentectomy

7 (10.8%)

17 (22.4%)

6 (12.2%)

12 (24.5%)

 Wedge

22 (33.8%)

53 (69.7%)

19 (38.8%)

31 (63.3%)

Chemotherapy

5.01

0.025

1.10

0.294

 Yes

11 (16.9%)

4 (5.2%)

6 (12.2%)

3 (6.1%)

 No

54 (83.1%)

72 (94.8%)

43 (87.8%)

46 (93.9%)